Overview

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
Phase:
PHASE1
Details
Lead Sponsor:
Stanford University
Collaborator:
Stemline Therapeutics, Inc.
Treatments:
Cladribine
Cytarabine
tagraxofusp